Skip to main content
Top
Published in: International Journal of Clinical Oncology 8/2023

Open Access 24-04-2023 | Human Papillomavirus | Invited Review Article

Etiology, diagnosis, treatment, and prevention of human papilloma virus-associated oropharyngeal squamous cell carcinoma

Authors: Hirotaka Shinomiya, Ken-ichi Nibu

Published in: International Journal of Clinical Oncology | Issue 8/2023

Login to get access

Abstract

Classical oropharyngeal squamous cell carcinoma (OPSCC) caused by alcohol consumption and smoking and HPV-associated OPSCC caused by human papillomavirus (HPV) infection have different etiologies, incidences, and prognoses. Therefore, the 8th American Joint committee on Cancer (AJCC) and Union for International Cancer Control (UICC) TNM classifications propose distinguishing HPV-associated OPSCC from classical OPSCC and classifying it as an independent disease. Therefore, this review provides an overview of HPV-associated OPSCC from the perspectives of epidemiology, carcinogenesis, development, diagnosis, treatment, and prevention. The incidence of HPV-associated OPSCC is increasing. Although HPV vaccination has been shown to be effective at reducing the incidence of cervical cancer, it is still unclear how it affects the incidence of HPV-associated OPSCC. Additionally, the prognosis of patients with HPV-associated OPSCC is extremely favorable compared to that of patients with classical OPSCC. Therefore, patients with HPV-associated OPSCC may undergo reduced-dose therapy, although attempts to reduce treatment intensity should be carefully planned to ensure they do not compromise oncological outcomes, and large-scale trials aimed at reducing treatment intensity are ongoing.
Literature
1.
go back to reference Mork J, Lie AK, Glattre E et al (2001) Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344:1125–1131PubMed Mork J, Lie AK, Glattre E et al (2001) Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344:1125–1131PubMed
2.
go back to reference Chaturvedi AK, Engels EA, Pfeiffer RM et al (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294–4301PubMedPubMedCentral Chaturvedi AK, Engels EA, Pfeiffer RM et al (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294–4301PubMedPubMedCentral
3.
go back to reference Senkomago V, Henley SJ, Thomas CC et al (2019) Human papillomavirus-attributable cancers - united states, 2012–2016. MMWR Morb Mortal Wkly Rep 68:724–728PubMedPubMedCentral Senkomago V, Henley SJ, Thomas CC et al (2019) Human papillomavirus-attributable cancers - united states, 2012–2016. MMWR Morb Mortal Wkly Rep 68:724–728PubMedPubMedCentral
4.
go back to reference Gillison ML, D’Souza G, Westra W et al (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100:407–420PubMed Gillison ML, D’Souza G, Westra W et al (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100:407–420PubMed
5.
go back to reference Craig SG, Anderson LA, Schache AG et al (2019) Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach. Br J Cancer 120:827–833PubMedPubMedCentral Craig SG, Anderson LA, Schache AG et al (2019) Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach. Br J Cancer 120:827–833PubMedPubMedCentral
6.
go back to reference Van Dyne EA, Henley SJ, Saraiya M et al (2018) Trends in human papillomavirus-associated cancers - united states, 1999–2015. MMWR Morb Mortal Wkly Rep 67:918–924PubMedPubMedCentral Van Dyne EA, Henley SJ, Saraiya M et al (2018) Trends in human papillomavirus-associated cancers - united states, 1999–2015. MMWR Morb Mortal Wkly Rep 67:918–924PubMedPubMedCentral
7.
go back to reference Mineta H, Ogino T, Amano HM et al (1998) Human papilloma virus (HPV) type 16 and 18 detected in head and neck squamous cell carcinoma. Anticancer Res 18:4765–4768PubMed Mineta H, Ogino T, Amano HM et al (1998) Human papilloma virus (HPV) type 16 and 18 detected in head and neck squamous cell carcinoma. Anticancer Res 18:4765–4768PubMed
8.
go back to reference Hama T, Tokumaru Y, Fujii M et al (2014) Prevalence of human papillomavirus in oropharyngeal cancer: a multicenter study in Japan. Oncology 87:173–182PubMed Hama T, Tokumaru Y, Fujii M et al (2014) Prevalence of human papillomavirus in oropharyngeal cancer: a multicenter study in Japan. Oncology 87:173–182PubMed
9.
go back to reference Deng Z, Hasegawa M, Matayoshi S et al (2011) Prevalence and clinical features of human papillomavirus in head and neck squamous cell carcinoma in Okinawa, southern Japan. Eur Arch Otorhinolaryngol 268:1625–1631PubMed Deng Z, Hasegawa M, Matayoshi S et al (2011) Prevalence and clinical features of human papillomavirus in head and neck squamous cell carcinoma in Okinawa, southern Japan. Eur Arch Otorhinolaryngol 268:1625–1631PubMed
10.
go back to reference Jun HW, Ji YB, Song CM et al (2021) Positive rate of human papillomavirus and its trend in head and neck cancer in South Korea. Front Surg 8:833048PubMed Jun HW, Ji YB, Song CM et al (2021) Positive rate of human papillomavirus and its trend in head and neck cancer in South Korea. Front Surg 8:833048PubMed
11.
go back to reference Cheng D, Rao Y, Qiu J et al (2022) survival outcomes related to treatment modalities in patients with oropharyngeal squamous cell carcinoma. Ear Nose Throat J. DO I:1455613221115608 Cheng D, Rao Y, Qiu J et al (2022) survival outcomes related to treatment modalities in patients with oropharyngeal squamous cell carcinoma. Ear Nose Throat J. DO I:1455613221115608
12.
go back to reference D’Souza G, Kreimer AR, Viscidi R et al (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944–1956PubMed D’Souza G, Kreimer AR, Viscidi R et al (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944–1956PubMed
13.
go back to reference Blumberg J, Monjane L, Prasad M et al (2015) Investigation of the presence of HPV related oropharyngeal and oral tongue squamous cell carcinoma in Mozambique. Cancer Epidemiol 39:1000–1005PubMedPubMedCentral Blumberg J, Monjane L, Prasad M et al (2015) Investigation of the presence of HPV related oropharyngeal and oral tongue squamous cell carcinoma in Mozambique. Cancer Epidemiol 39:1000–1005PubMedPubMedCentral
14.
go back to reference Drake VE, Fakhry C, Windon MJ et al (2021) Timing, number, and type of sexual partners associated with risk of oropharyngeal cancer. Cancer 127:1029–1038PubMed Drake VE, Fakhry C, Windon MJ et al (2021) Timing, number, and type of sexual partners associated with risk of oropharyngeal cancer. Cancer 127:1029–1038PubMed
15.
go back to reference Ferris RL, Westra W (2023) Oropharyngeal carcinoma with a special focus on hpv-related squamous cell carcinoma. Annu Rev Pathol 18:515–535PubMed Ferris RL, Westra W (2023) Oropharyngeal carcinoma with a special focus on hpv-related squamous cell carcinoma. Annu Rev Pathol 18:515–535PubMed
16.
go back to reference Roberts JN, Buck CB, Thompson CD et al (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13:857–861PubMed Roberts JN, Buck CB, Thompson CD et al (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13:857–861PubMed
17.
go back to reference Sano D, Oridate N (2016) The molecular mechanism of human papillomavirus-induced carcinogenesis in head and neck squamous cell carcinoma. Int J Clin Oncol 21:819–826PubMed Sano D, Oridate N (2016) The molecular mechanism of human papillomavirus-induced carcinogenesis in head and neck squamous cell carcinoma. Int J Clin Oncol 21:819–826PubMed
18.
go back to reference McIlwain WR, Sood AJ, Nguyen SA et al (2014) Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 140:441–447PubMed McIlwain WR, Sood AJ, Nguyen SA et al (2014) Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 140:441–447PubMed
19.
go back to reference Lewis JS (2017) Morphologic diversity in human papillomavirus-related oropharyngeal squamous cell carcinoma: catch me if you can! Mod Pathol 30:S44–S53PubMed Lewis JS (2017) Morphologic diversity in human papillomavirus-related oropharyngeal squamous cell carcinoma: catch me if you can! Mod Pathol 30:S44–S53PubMed
20.
go back to reference Yasui T, Morii E, Yamamoto Y et al (2014) Human papillomavirus and cystic node metastasis in oropharyngeal cancer and cancer of unknown primary origin. PLoS ONE 9:e95364PubMedPubMedCentral Yasui T, Morii E, Yamamoto Y et al (2014) Human papillomavirus and cystic node metastasis in oropharyngeal cancer and cancer of unknown primary origin. PLoS ONE 9:e95364PubMedPubMedCentral
21.
go back to reference Tham T, Ahn S, Frank D et al (2020) Anatomical subsite modifies survival in oropharyngeal squamous cell carcinoma: national cancer database study. Head Neck 42:434–445PubMed Tham T, Ahn S, Frank D et al (2020) Anatomical subsite modifies survival in oropharyngeal squamous cell carcinoma: national cancer database study. Head Neck 42:434–445PubMed
22.
go back to reference O’Sullivan B, Huang SH, Su J et al (2016) Development and validation of a staging system for HPV-related oropharyngeal cancer by the international collaboration on oropharyngeal cancer network for staging (ICON-S): a multicentre cohort study. Lancet Oncol 17:440–451PubMed O’Sullivan B, Huang SH, Su J et al (2016) Development and validation of a staging system for HPV-related oropharyngeal cancer by the international collaboration on oropharyngeal cancer network for staging (ICON-S): a multicentre cohort study. Lancet Oncol 17:440–451PubMed
23.
go back to reference Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35PubMedPubMedCentral Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35PubMedPubMedCentral
24.
go back to reference Shinomiya H, Kubo M, Saito Y et al (2017) Prognostic value of ALDH2 polymorphism for patients with oropharyngeal cancer in a Japanese population. PLoS ONE 12:e0187992PubMedPubMedCentral Shinomiya H, Kubo M, Saito Y et al (2017) Prognostic value of ALDH2 polymorphism for patients with oropharyngeal cancer in a Japanese population. PLoS ONE 12:e0187992PubMedPubMedCentral
25.
go back to reference Saito Y, Yoshida M, Ushiku T et al (2013) Prognostic value of p16 expression and alcohol consumption in Japanese patients with oropharyngeal squamous cell carcinoma. Cancer 119:2005–2011PubMed Saito Y, Yoshida M, Ushiku T et al (2013) Prognostic value of p16 expression and alcohol consumption in Japanese patients with oropharyngeal squamous cell carcinoma. Cancer 119:2005–2011PubMed
26.
go back to reference Posner MR, Lorch JH, Goloubeva O et al (2011) Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 22:1071–1077PubMedPubMedCentral Posner MR, Lorch JH, Goloubeva O et al (2011) Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 22:1071–1077PubMedPubMedCentral
27.
go back to reference Schache AG, Liloglou T, Risk JM et al (2011) Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 17:6262–6271PubMedPubMedCentral Schache AG, Liloglou T, Risk JM et al (2011) Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 17:6262–6271PubMedPubMedCentral
28.
go back to reference Weinstein GS, O’Malley BW, Snyder W et al (2007) Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg 133:1220–1226PubMed Weinstein GS, O’Malley BW, Snyder W et al (2007) Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg 133:1220–1226PubMed
29.
go back to reference Cracchiolo JR, Baxi SS, Morris LG et al (2016) Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: national cancer data base. Cancer 122:1523–1532PubMed Cracchiolo JR, Baxi SS, Morris LG et al (2016) Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: national cancer data base. Cancer 122:1523–1532PubMed
30.
go back to reference de Almeida JR, Li R, Magnuson JS et al (2015) Oncologic outcomes after transoral robotic surgery: a multi-institutional study. JAMA Otolaryngol Head Neck Surg 141:1043–1051PubMedPubMedCentral de Almeida JR, Li R, Magnuson JS et al (2015) Oncologic outcomes after transoral robotic surgery: a multi-institutional study. JAMA Otolaryngol Head Neck Surg 141:1043–1051PubMedPubMedCentral
31.
go back to reference Sinha P, Haughey BH, Kallogjeri D et al (2019) Long-term analysis of transorally resected p16 + oropharynx cancer: outcomes and prognostic factors. Laryngoscope 129:1141–1149PubMed Sinha P, Haughey BH, Kallogjeri D et al (2019) Long-term analysis of transorally resected p16 + oropharynx cancer: outcomes and prognostic factors. Laryngoscope 129:1141–1149PubMed
32.
go back to reference Sethia R, Yumusakhuylu AC, Ozbay I et al (2018) Quality of life outcomes of transoral robotic surgery with or without adjuvant therapy for oropharyngeal cancer. Laryngoscope 128:403–411PubMed Sethia R, Yumusakhuylu AC, Ozbay I et al (2018) Quality of life outcomes of transoral robotic surgery with or without adjuvant therapy for oropharyngeal cancer. Laryngoscope 128:403–411PubMed
33.
go back to reference Nichols AC, Theurer J, Prisman E et al (2022) Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. J Clin Oncol 40:866–875PubMed Nichols AC, Theurer J, Prisman E et al (2022) Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. J Clin Oncol 40:866–875PubMed
34.
go back to reference Sano D, Shimizu A, Tateya I et al (2021) Current status of transoral Surgery for patients with early-stage pharyngeal and laryngeal cancers in Japan. Front Oncol 11:804933PubMedPubMedCentral Sano D, Shimizu A, Tateya I et al (2021) Current status of transoral Surgery for patients with early-stage pharyngeal and laryngeal cancers in Japan. Front Oncol 11:804933PubMedPubMedCentral
35.
go back to reference Sano D, Shimizu A, Tateya I et al (2021) Treatment outcomes of transoral robotic and non-robotic surgeries to treat oropharyngeal, hypopharyngeal, and supraglottic squamous cell carcinoma: a multi-center retrospective observational study in Japan. Auris Nasus Larynx 48:502–510PubMed Sano D, Shimizu A, Tateya I et al (2021) Treatment outcomes of transoral robotic and non-robotic surgeries to treat oropharyngeal, hypopharyngeal, and supraglottic squamous cell carcinoma: a multi-center retrospective observational study in Japan. Auris Nasus Larynx 48:502–510PubMed
36.
go back to reference Park YM, Kim HR, Cho BC et al (2017) Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal squamous cell carcinoma. Oral Oncol 75:16–21PubMed Park YM, Kim HR, Cho BC et al (2017) Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal squamous cell carcinoma. Oral Oncol 75:16–21PubMed
37.
go back to reference Mensour EA, Alam S, Mawani S et al (2022) What is the future of treatment de-escalation for HPV-positive oropharyngeal cancer? A review of ongoing clinical trials. Front Oncol 12:1067321PubMedPubMedCentral Mensour EA, Alam S, Mawani S et al (2022) What is the future of treatment de-escalation for HPV-positive oropharyngeal cancer? A review of ongoing clinical trials. Front Oncol 12:1067321PubMedPubMedCentral
38.
go back to reference Gillison ML, Trotti AM, Harris J et al (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393:40–50PubMed Gillison ML, Trotti AM, Harris J et al (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393:40–50PubMed
39.
go back to reference Mehanna H, Robinson M, Hartley A et al (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393:51–60PubMedPubMedCentral Mehanna H, Robinson M, Hartley A et al (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393:51–60PubMedPubMedCentral
40.
go back to reference Yom SS, Torres-Saavedra P, Caudell JJ et al (2021) Reduced-dose radiation therapy for hpv-associated oropharyngeal carcinoma (NRG oncology HN002). J Clin Oncol 39:956–965PubMedPubMedCentral Yom SS, Torres-Saavedra P, Caudell JJ et al (2021) Reduced-dose radiation therapy for hpv-associated oropharyngeal carcinoma (NRG oncology HN002). J Clin Oncol 39:956–965PubMedPubMedCentral
41.
go back to reference Robert L. Ferris YF, Gregory S. Weinstein, Shuli Li, Harry Quon, Ranee Mehra, Joaquin J. Garcia, Christine H. Chung, Maura L. Gillison, Umamaheswar Duvvuri, Bert W. O'malley, Enver Ozer, Giovana R. Thomas, Wayne Koch, Michael Elliot Kupferman, Richard Bryan Bell, Nabil F. Saba, Miriam Lango, Eduardo Mendez, Barbara Burtness: Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311), 2020 Robert L. Ferris YF, Gregory S. Weinstein, Shuli Li, Harry Quon, Ranee Mehra, Joaquin J. Garcia, Christine H. Chung, Maura L. Gillison, Umamaheswar Duvvuri, Bert W. O'malley, Enver Ozer, Giovana R. Thomas, Wayne Koch, Michael Elliot Kupferman, Richard Bryan Bell, Nabil F. Saba, Miriam Lango, Eduardo Mendez, Barbara Burtness: Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311), 2020
42.
go back to reference Yang MQ, Liu YC, Sui JD et al (2022) Reduced-dose radiation in human papillomavirus-associated oropharyngeal carcinoma can improve outcome: a systematic review and meta-analysis. Ann Transl Med 10:1391PubMedPubMedCentral Yang MQ, Liu YC, Sui JD et al (2022) Reduced-dose radiation in human papillomavirus-associated oropharyngeal carcinoma can improve outcome: a systematic review and meta-analysis. Ann Transl Med 10:1391PubMedPubMedCentral
43.
go back to reference Lei J, Ploner A, Elfström KM et al (2020) HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 383:1340–1348PubMed Lei J, Ploner A, Elfström KM et al (2020) HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 383:1340–1348PubMed
44.
go back to reference Ogilvie GS, Naus M, Money DM et al (2015) Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: an ecological analysis. Int J Cancer 137:1931–1937PubMed Ogilvie GS, Naus M, Money DM et al (2015) Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: an ecological analysis. Int J Cancer 137:1931–1937PubMed
45.
go back to reference Palmer T, Wallace L, Pollock KG et al (2019) Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12–13 in Scotland: retrospective population study. BMJ 365:l1161PubMedPubMedCentral Palmer T, Wallace L, Pollock KG et al (2019) Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12–13 in Scotland: retrospective population study. BMJ 365:l1161PubMedPubMedCentral
46.
go back to reference Shiko Y, Konno R, Konishi H et al (2020) Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women. BMC Infect Dis 20:808PubMedPubMedCentral Shiko Y, Konno R, Konishi H et al (2020) Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women. BMC Infect Dis 20:808PubMedPubMedCentral
47.
go back to reference Sekine M, Yamaguchi M, Kudo R et al (2021) Suspension of proactive recommendations for HPV vaccination has led to a significant increase in HPV infection rates in young Japanese women: real-world data. Lancet Reg Health West Pac 16:100300PubMedPubMedCentral Sekine M, Yamaguchi M, Kudo R et al (2021) Suspension of proactive recommendations for HPV vaccination has led to a significant increase in HPV infection rates in young Japanese women: real-world data. Lancet Reg Health West Pac 16:100300PubMedPubMedCentral
48.
go back to reference Cho H, Kishikawa T, Tokita Y et al (2020) Prevalence of human papillomavirus in oral gargles and tonsillar washings. Oral Oncol 105:104669PubMed Cho H, Kishikawa T, Tokita Y et al (2020) Prevalence of human papillomavirus in oral gargles and tonsillar washings. Oral Oncol 105:104669PubMed
49.
go back to reference Berenson AB, Hirth JM, Chang M (2022) Prevalence of oral human papillomavirus infection: impact of sex, race/ethnicity, and vaccination status. Clin Infect Dis 74:1230–1236PubMed Berenson AB, Hirth JM, Chang M (2022) Prevalence of oral human papillomavirus infection: impact of sex, race/ethnicity, and vaccination status. Clin Infect Dis 74:1230–1236PubMed
51.
go back to reference Maruyama H, Yasui T, Ishikawa-Fujiwara T et al (2014) Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Sci 105:409–417PubMedPubMedCentral Maruyama H, Yasui T, Ishikawa-Fujiwara T et al (2014) Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Sci 105:409–417PubMedPubMedCentral
52.
go back to reference HPV vaccination uptake | National Cancer Control Indicators (canceraustralia.gov.au), HPV vaccination uptake | National Cancer Control Indicators (canceraustralia.gov.au),
53.
go back to reference Damgacioglu H, Sonawane K, Chhatwal J et al (2022) Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: a modeling study. Lancet Reg Health Am 8:100143PubMed Damgacioglu H, Sonawane K, Chhatwal J et al (2022) Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: a modeling study. Lancet Reg Health Am 8:100143PubMed
54.
go back to reference Brisson M, Kim JJ, Canfell K et al (2020) Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet 395:575–590PubMedPubMedCentral Brisson M, Kim JJ, Canfell K et al (2020) Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet 395:575–590PubMedPubMedCentral
Metadata
Title
Etiology, diagnosis, treatment, and prevention of human papilloma virus-associated oropharyngeal squamous cell carcinoma
Authors
Hirotaka Shinomiya
Ken-ichi Nibu
Publication date
24-04-2023
Publisher
Springer Nature Singapore
Published in
International Journal of Clinical Oncology / Issue 8/2023
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-023-02336-8

Other articles of this Issue 8/2023

International Journal of Clinical Oncology 8/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine